ERBB2 and breast carcinoma: Indeed, a majority of clinical breast cancers showed positive staining for HLA-G (Fig. 1a), and a quantitative analysis demonstrated that the HLA-G level was not associated with the expression of HER2, a specific biomarker for breast cancer subtyping (Fig. 1b).